EGF Theramed Health Corp.
TMED
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.40% | 78.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 41.40% | 78.22% | |||
| Operating Income | -41.40% | -78.22% | |||
| Income Before Tax | -72.78% | -16.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -72.78% | -16.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 438.89% | -79.31% | |||
| Net Income | -59.60% | -39.66% | |||
| EBIT | -41.40% | -78.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -60.47% | -38.71% | |||
| Normalized Basic EPS | -53.85% | -62.50% | |||
| EPS Diluted | -60.47% | -38.71% | |||
| Normalized Diluted EPS | -53.85% | -62.50% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||